Swiss National Bank Boosts Holdings in Boston Scientific Corporation $BSX

Swiss National Bank lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 7.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,477,200 shares of the medical equipment provider’s stock after buying an additional 320,400 shares during the quarter. Swiss National Bank owned about 0.30% of Boston Scientific worth $480,896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also bought and sold shares of the company. 1248 Management LLC purchased a new position in shares of Boston Scientific in the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific in the first quarter worth $27,000. Sound Income Strategies LLC lifted its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the period. Princeton Global Asset Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Boston Scientific in the 2nd quarter worth about $37,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

Shares of BSX opened at $96.63 on Friday. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a market capitalization of $143.25 billion, a P/E ratio of 51.68, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The firm has a 50 day moving average of $99.09 and a 200 day moving average of $102.43. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter last year, the company earned $0.63 EPS. The company’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,782 shares of company stock valued at $17,742,314 over the last quarter. 0.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BSX has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a research note on Friday, October 17th. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a report on Monday, September 29th. Robert W. Baird boosted their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Wells Fargo & Company raised their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Finally, Truist Financial lifted their price objective on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.